Assessment of Cardiac Allograft Vasculopathy (CAV) by Optical Coherence Tomography (OCT)
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 150
- 试验地点
- 4
- 主要终点
- Rapid progression of cardiac allograft vasculopathy
研究概览
简要总结
Cardiac allograft vasculopathy (CAV) is characterized by marked intimal proliferation and concentric vascular thickening and fibrosis. CAV remains the leading cause of late morbidity and mortality in heart transplant recipients. Optical coherence tomography (OCT) is a new generation catheter-based modality that acquires images at a spatial resolution of 10-20 μm which is 10-fold greater than that of intravascular ultrasound (IVUS). OCT is currently the most sensitive imaging technique for early CAV detection. Recent studies proved that circulating human leukocyte antigen (HLA) directed donor-specific antibodies correlate with increased mortality and CAV. Contradiction of scientific results has been reported regarding increased resting heart rate and development of CAV. Larger prospective studies using more sensitive CAV detecting methods are required to enhance our understanding. Novel immunosuppressants, mechanistic target of rapamycin (mTOR) inhibitors, may attenuate CAV progression and may improve long-term allograft survival owing to favorable coronary remodeling.
Aim of the study: Use OCT imaging for identification of patients with early rapid progression of CAV (rapid progressors) and to identify the critical risk factors responsible for CAV progression. The impact of conventional and heart transplant (HTx) specific risk factors, such as donor-specific antibodies or rapid heart rate will be studied in a prospective, national-level cohort study. The implication of OCT results will lead to adjustment of immunosuppressive therapy in one year after heart transplant to prevent further progression of the disease in CAV rapid progressors.
Working hypotheses:
- Patients with rapid progression of cardiac allograft vasculopathy can be identified by increased titers of donor specific anti-human leukocyte antigen (anti-HLA) and/or antibodies against major histocompatibility complex (MHC) class I-related chain A (MICA) antibodies.
- Specific high-risk characteristics of anti-HLA antibodies can be identified that are associated with particularly high rate of CAV progression (vascular complement activation in biopsies, certain HLA haplotypes).
- Tachycardia in heart transplant recipients represents a risk factor for development of cardiac allograft vasculopathy.
- Influence of anti-HLA antibodies and increased heart rate is independent of already established risk factors of CAV.
详细描述
Cardiac allograft vasculopathy (CAV) represents the leading cause of late morbidity and mortality in heart transplant recipients and accounts for a second of all-cause mortality at 3 years. Development of CAV is a complex process involving intimal thickening, atherosclerosis, thrombosis and vasculitis by histology, but ultimately, intimal hyperplasia is the predominant cause of lumen narrowing, leading to ischemia and graft failure. In distinction from general coronary atherosclerosis, which is marked by focal and eccentric fibrofatty atheroma, CAV affects diffusely the entire coronary vasculature with marked intimal proliferation and concentric vascular thickening and fibrosis.
Optical coherence tomography (OCT), compared with IVUS, is more sensitive for early detection of CAV. OCT is a new generation catheter-based modality that acquires images at a spatial resolution of 10-20 μm which is 10-fold greater than that of IVUS. OCT could obviously identify the layer of media as a lower-echoic line, which could not be identified by IVUS. When assessing the quality of an intracoronary structure accurately, OCT seems to have more potential than IVUS.
The endothelial cells of the cardiac vasculature express human leukocyte antigens (HLA) and others, such as vimentin and major histocompatibility complex (MHC) class I-related chain A (MICA), and appear to be primary targets of cell-mediated and humoral immune responses after heart transplant (HTx). Circulating antibodies mediate rejection through complement activation and fixation on graft endothelium, thereby predisposing the patient to graft loss, accelerated cardiac allograft vasculopathy, and death. The rate of allosensitized patients (patients with circulating antibodies against donor antigens) on waiting lists is increasing as a consequence of growing numbers of retransplants and assist-device implantations. Allosensitization is a consequence of exposure to disparate HLA molecules during pregnancy, blood/platelet transfusions, or after cardiac repairs with homograft material, but may occur in some patients even without any of these triggers from unknown reasons.
Orthotopic heart transplantation is accompanied by sympathetic and parasympathetic denervation. The subsequent heart rate is usually higher and the circadian variation is low due to elimination of the vagus nerve effect. It is known that persistent increase in heart rate contributes to the pathogenesis of vascular diseases.
AIMS OF THE PROJECT The aim of this study is to use OCT imaging for identification of patients with early rapid progression of cardiac allograft vasculopathy (rapid progressors) and to identify the critical risk factors responsible for CAV progression. The impact of conventional and HTx-specific risk factors, such as donor-specific antibodies (using the most sensitive methods for its measurement) or rapid heart rate (using repeated Holter monitoring) will be studied in a prospective, national-level cohort study. The implication of OCT results will lead to adjustment of immunosuppressive therapy in one year after heart transplant to prevent further progression of the disease in CAV rapid progressors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All new cardiac transplant recipients ≥18 years
排除标准
- •Severe renal dysfunction (GFR less than 30 ml/min)
- •Active infection
- •Active cellular/humoral rejection
- •Unwilling or unable to sign informed consent
结局指标
主要结局
Rapid progression of cardiac allograft vasculopathy
时间窗: 1 year
OCT imaging will be used for identification of patients with early rapid progression of cardiac allograft vasculopathy. Normalized intimal volume, normalized lumen volume, mean intima thickness and mean intima-to-media ratio (I/M) will be used to identify fast progression of CAV.
次要结局
- Donor specific anti-HLA and/or MICA antibodies(1 year)
- Heart rate(1 year)
研究者
Michal Pazdernik, MD
M.D.
Institute for Clinical and Experimental Medicine
